Equity Details
Price & Market Data
Price: $0.569
Daily Change: -$0.0116 / 2.04%
Daily Range: $0.569 - $0.60
Market Cap: $3,828,459
Daily Volume: 16,290
Performance Metrics
1 Week: -4.82%
1 Month: -15.59%
3 Months: 3.53%
6 Months: -25.21%
1 Year: -57.24%
YTD: -22.91%
About Galmed Pharmaceuticals Ltd. (GLMD)
Comprehensive market data and analysis for Galmed Pharmaceuticals Ltd. (GLMD). Current price: 0.569, daily change: -$0.0116 / 2.04%. Market cap: 3,828,459. View detailed YTD, 1-week, and 1-month performance.
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
